文献速递头颈与中枢神经肿瘤

血浆EB病毒DNA液体活检可表征生物性复发以预测非播散性鼻咽癌的肿瘤复发

Liquid biopsy with plasma Epstein-Barr virus DNA characterizes biological relapse for the prediction of cancer recurrence in non-disseminated nasopharyngeal carcinoma.
PubMed 文献 · Eur J Cancer · 2024-10-26

该回顾性研究筛查950例治疗后3个月内达到完全缓解的非播散性鼻咽癌患者,将随访中可检测到EBV DNA但无临床复发证据定义为DNA反弹。两次阳性检测预测复发的敏感度0.56、特异度0.95、阳性预测值0.66、阴性预测值0.93、准确度0.90;连续阈值(EBV DNA 1≥40 copies/ml或EBV DNA 2≥100 copies/ml)定义的高危亚组最终复发率77.9%、3年DFS仅20.5%。卡培他滨或S1预防性干预较观察显著改善3年DFS。

要点

  • 两次EBV DNA阳性检测可定义为生物性复发,预测复发的特异度0.95、准确度0.90。
  • 连续阈值(EBV DNA 1≥40 copies/ml或EBV DNA 2≥100 copies/ml)定义的高危亚组复发率77.9%、3年DFS仅20.5%。
  • 卡培他滨或S1预防性干预较观察显著改善3年DFS。

核心结论

  • 最早两次EBV DNA阳性检测代表生物性复发标志物,可早期发现EBV相关鼻咽癌的临床复发。
  • 对于高危生物性复发,抢先干预提供潜在生存获益。

研究设计与样本

  • 回顾性筛查950例治疗后3个月内达到完全缓解的非播散性鼻咽癌患者。
  • 随访中可检测到EBV DNA但无临床复发证据定义为DNA反弹。

主要发现

  • 肿瘤复发在EBV DNA持续阴性组为6.6%、单次阳性检测组为10.1%、≥2次阳性检测组为65.8%。
  • EBV DNA反弹超过两次与其他两组相比与更差的无病生存(DFS)、无局部区域复发生存(LRRFS)和无远处转移生存(DMFS)相关。
  • 使用两次阳性检测预测复发的敏感度0.56、特异度0.95、阳性预测值0.66、阴性预测值0.93、准确度0.90。
  • 连续阈值(EBV DNA 1≥40 copies/ml或EBV DNA 2≥100 copies/ml)进一步定义高危亚组,最终复发率77.9%、3年DFS仅20.5%。
  • 卡培他滨或S1预防性医学干预较观察显著改善3年DFS。

关键数值与推荐

  • 两次阳性检测预测复发的敏感度0.56、特异度0.95、阳性预测值0.66、阴性预测值0.93、准确度0.90,故 deemed 为生物性复发。
  • 连续阈值:EBV DNA 1≥40 copies/ml或EBV DNA 2≥100 copies/ml定义高危亚组,最终复发率77.9%、3年DFS 20.5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate whether a bounce in plasma Epstein-Barr virus (EBV) DNA during posttreatment surveillance of nasopharyngeal carcinoma (NPC) informs the risk of clinical recurrence and its implication for early therapeutic intervention. METHODS: 950 non-disseminated NPC patients with completed remission in 3 months after treatment were retrospectively screened. Detectable EBV DNA with no evidence of clinical relapse during follow-up was deemed as DNA bounce. The diagnostic and prognostic performance of EBV DNA bounce was assessed for subsequent failures. RESULTS: Tumor recurrence occurred in 6.6 %, 10.1 % and 65.8 % in the group with persistently negative EBV DNA, single positive test and ≥ 2 positive tests, respectively. EBV DNA bounce over twice was associated with worse disease-free survival (DFS), locoregional recurrence-free survival (LRRFS), and distant metastasis-free survival (DMFS) than the other two groups. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy for the prediction of recurrence were 0.56, 0.95, 0.66, 0.93 and 0.90 using two positive tests, which were hence deemed as biological relapse. Serial cutoffs (EBV DNA 1 ≥ 40 copies/ml or EBV DNA 2 ≥100 copies/ml) further defined a high-risk subgroup with an eventual recurrence rate of 77.9 % and 3-year DFS of merely 20.5 %. Prophylactic medical intervention with capecitabine or S1 significantly improved the 3-year DFS when compared to those with observation. CONCLUSIONS: The earliest two positive tests of EBV DNA represent a biomarker of biological relapse that allows early detection of clinical recurrence in EBV-related NPC. For high-risk biological relapse, preemptive intervention provides potential survival benefits.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Zhang Q, Zhu L, Lv W, et al. Liquid biopsy with plasma Epstein-Barr virus DNA characterizes biological relapse for the prediction of cancer recurrence in non-disseminated nasopharyngeal carcinoma. Eur J Cancer. 2024. PMID: 39486162. doi:10.1016/j.ejca.2024.115098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。